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Cancer treatment is being revolutionized through the use of
targeted and immunotherapy-based treatments. Infectious dis-
eases clinicians have traditionally associated cancer therapy with
infectious complications as a result of immunosuppressive effects;
however, many novel treatments have immunomodulatory ef-
fects that may mimic infectious diseases. BRAF and mitogen-
activated protein kinase kinase (MEK) inhibitors (e.g. dabrafenib
(DAB), ± trametinib (TRAM)) are molecular therapies used for
the treatment of advancedmelanoma that are also being trialled in
other tumours including papillary thyroid cancer, colorectal
cancer and ovarian cancer. Fever is a frequent complication of
BRAF and MEK inhibitors [1,2]. Infectious diseases clinicians are
therefore increasingly likely to consult on such patients and need
to be aware of the toxicities of these agents to avoid unnecessary
investigations and antimicrobial use. Because of this, we reviewed
all patients with advanced melanoma treated with DAB/TRAM in
our centre over a 4-year period (2011–15) to determine the
frequency and nature of DAB/TRAM reactions.
All patients that had received DAB/TRAM for advanced
melanoma at the Austin Hospital, Melbourne, Australia were
identiﬁed through pharmacy records and their medical records
were retrospectively analysed. Patients received either DAB
alone at a dose of 150 mg twice-daily or combination therapy
with DAB 150 mg twice-daily and TRAM 2 mg daily. Patients
undergoing clinical trials were included in the analysis.Clinical Microbiology and Infection © 2015 European Society of CData collected included patient demographics, details
regarding febrile episodes (cause, clinical features, management
(hospitalization, investigations, treatment discontinuation and
steroid use)) and clinical outcomes. Febrile episodes were
deﬁned as any fever38.0°C, with potential causes for the fever
deﬁned as either due to infection or DAB/TRAM (DAB/TRAM-
related febrile episode (DTFE)) if no alternative cause was
found. Occurrence of pyrexial symptoms (e.g. chills, myalgias,
sweats) without fever was not considered an episode. Other
deﬁnitions used were as follows: tachycardia (heart rate >100
beats/min); hypotension (systolic blood pressure <90 mmHg, or
decrease in systolic blood pressure >40 mmHg); and resolution
of febrile episode (24-h period of temperature 37.5°C).
Approval was obtained from the Austin Health Human
Research and Ethics Committee to undertake the study. Sta-
tistical analysis was performed using STATA/IC 12.1 (StataCorp,
College Station, TX, USA). Fisher’s exact test and chi-squared
test were used to compare categorical variables, as appropriate.
Thirty-three patients (median age 58 years, range 34–85 years;
23 (70%) male) received DAB/TRAM therapy (28 DAB/TRAM,
ﬁve DAB alone) for a total of 321.1 patient-months. There were
41 febrile episodes in 18/33 (55%) patients. DTFE accounted for
38 (88%) episodes and only 3 (12%) were due to infection. Pa-
tients had amean of 2.2DTFE (range 1–5) that occurred amedian
of 36 days (mean ± SD 50 ± 45 days, range 2–146 days) after
commencement of treatment or a median of 28 days (mean ± SD
62 ± 59 days, range 4–180 days) after re-commencement of
treatment.
The clinical characteristics of DTFE are summarized in
Table 1. Factors associated with DTFE included rigors (13/38
(34%) episodes, 7/33 (21%) patients) and rash (7/38 episodes
(8%); 3/33 (9%) patients), while hypotension (2/38 episodes
(5%), 2/33 (6%) patients) and neutrophilia (1/30 (3%) episodes,
1/33 (3%) patients) were uncommon. There were no localizing
features in any DTFE. Mean C-reactive protein during episodes
was 78 ± 47 mg/L (range 1.5–166 mg/L). Among the three
episodes of infection-associated febrile episodes (upper respi-
ratory tract infection, hospital-acquired pneumonia and empy-
ema), localizing features (3/3 (100%), p <0.0001), hypotension
(2/3 (66%), p 0.021), tachycardia (2/3 (66%), p 0.035) and a
C-reactive protein > 200 mg/L (2/3 (66%), p 0.0037) were all
more common than for DTFE. Of the three patients who had
infection-associated febrile episodes, two also had DTFE and
2/3 (67%) died due to their infection.
Management of DTFE is summarized in Table 1. Patients were
hospitalized in 14/38 episodes (37%) for a median of 4 days
(range 2–12 days). Antimicrobials were administered empirically
in 11/38 episodes (29%; vancomycin, 1; piperacillin/tazobactam,
2; ceftriaxone, 5; ﬂucloxacillin, 4; cephazolin/cephalexin, 2;Clin Microbiol Infect 2015; 21: e77–e78
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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TABLE 1. Clinical features and management of febrile
episodes (n [ 38) linked to debrafenib and trametinib use in
advanced melanoma
Feature Total (n [ 38)
Clinical features of febrile episodes






Skin rash 7 (18%)
Localizing symptoms 0 (0%)
C-reactive protein – mean ± SD (range) 78 ± 47 mg/L (range 1.5–166 mg/L)
Neutrophil count – mean ± SD (range) 4.4 × 109 ± 2.3 × 109 cells/L
(range 1.1 × 109 to 12.7 × 109
cells/L)
Management and outcomes of
febrile episodes
Hospitalization 14 (37%)
Median duration of hospitalization 4 days (range 2–12 days)
Empirical antibiotic use 11 (29%)
Median time to resolution of fever 2 days (range 1–17 days)
Melanoma treatment interruption 24 (63%)
Median treatment interruption duration 2.5 days (range 1–13 days)
Received corticosteroid therapy 15 (39%)
Median prednisolone dose used 20 mg (range 5–25 mg)
Corticosteroids given as ‘secondary
prophylaxis’
13 (34%)
Median prednisolone dose used as
secondary prophylaxis
10 mg (range 5–30 mg)
e78 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIamoxicillin/clavulanic acid, 1; azithromycin/doxycycline, 4) for a
total of 80 days. Melanoma treatment interruption occurred in
24/38 (63%) episodes and corticosteroids were given in 15/38
(39%) episodes. Fevers resolved after a median of 3 days (range
1–17 days) for episodes where treatment was discontinued. In
13/38 (34%) episodes patients continued to receive corticoste-
roids as ‘secondary prophylaxis’ for fevers. Of patients that did
not have DTFE, 9/16 (56%) were receiving corticosteroids as
symptomatic treatment of metastases.
Although febrile reactions have previously been reported
with BRAF/MEK inhibitor therapy, the relative frequency (55%
patients) and clinical characteristics of these reactions have not
been accurately deﬁned. In fact, DTFE was by far the most
common (93%) reason for febrile episodes in these patients,
who typically had no localizing features (100%), but rigors
(34%) and occasionally rash (8%), together with only a modest
rise in C-reactive protein; without signs of sepsis such as hy-
potension or neutrophilia. This clinical clustering has not been
fully appreciated previously [1–5], despite its likely utility for
clinicians faced with a febrile patient with melanoma. Impor-
tantly, DTFE appear to be short-lived with rapid resolution of
fevers following discontinuation of treatment and respond well
to moderate-dose corticosteroid treatment. Persistence of
fevers beyond 4 days despite these measures helps to excludeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectBRAF/MEK inhibitors as a cause of fever. Frustratingly, the
pathogenesis of fever due to BRAF/MEK inhibitor therapy
remains unclear [4].
This study had some limitations. First, due to its retrospec-
tive nature there was no standard approach to the management
of fevers, so making it difﬁcult to assess the relative contribu-
tions of melanoma treatment interruption and use of cortico-
steroids. Second, there were (interestingly) few episodes of
infection-related fevers in our study population, making direct
comparison with DTFE less deﬁnitive. Finally, as BRAF/MEK
inhibitors are now being used for other non-melanoma solid
tumours, we cannot be certain that the same pattern of febrile
reactions will occur in such settings.
Clinicians need to be increasingly aware of the adverse
effects of BRAF/MEK inhibitor therapy for melanoma, such that
while a thorough work-up for infectious causes will almost
always be required, unnecessary excess hospitalization and
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